We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 10, 2020

Donor-Derived CD19 CAR T–Cell Therapy of Relapsed CD19-Positive B-ALL Following Allotransplant



Additional Info

Disclosure statements are available on the authors' profiles:

Donor-Derived CD19 CAR-T Cell Therapy of Relapse of CD19-Positive B-ALL Post Allotransplant
Leukemia 2020 Oct 19;[EPub Ahead of Print], C Zhang, XQ Wang, RL Zhang, F Liu, Y Wang, ZL Yan, YP Song, T Yang, P Li, Z Wang, YY Ma, L Gao, Y Liu, L Gao, PY Kong, J Liu, X Tan, JF Zhong, YQ Chen, AB Liang, JH Ren, ZY Li, J Cao, QL Gao, J Zhou, Y Gao, D Zhang, FY Fan, MZ Han, RP Gale, X Zhang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading